Korean biotech company ExoDiscovery moved its headquarters to Cedar Park in June.

In a nutshell

ExoDiscovery develops technology targeting earlier detection of cancer-specific biomarkers. Its main focus is improving turnaround times and accuracy rates to improve patient outcomes, according to the company's website.

A closer look

ExoDiscovery was founded in 2018 in South Korea by Yoon Cho, a biomedical engineering professor at Ulsan National Institute of Science & Technology, and Kyu Lee, a biotechnology entrepreneur.


The company currently has two main products: ExoDiscovery Detect and ExoDiscovery Monitor.

ExoDiscovery Detect has a 24-hour turnaround time with 97% accuracy from a single standard blood draw. ExoDiscovery Monitor provides the same 24-hour turnaround time from a standard blood draw, but tracks resistance to treatment with a quicker turnaround time, so oncologists can “make data-driven decisions about therapy continuation or modification,” according to the ExoDiscovery website.